Profile data is unavailable for this security.
About the company
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
- Revenue in USD (TTM)0.00
- Net income in USD-56.98m
- Incorporated2012
- Employees36.00
- LocationQuince Therapeutics Inc601 Gateway Boulevard, Suite 1250SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (415) 910-5717
- Fax+1 (302) 655-5049
- Websitehttps://quincetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LianBio - ADR | 0.00 | -87.98m | 9.83m | 163.00 | -- | 0.0482 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Imunon Inc | 0.00 | -14.33m | 9.98m | 25.00 | -- | 2.65 | -- | -- | -10.20 | -10.20 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -122.58 | -57.72 | -208.59 | -70.83 | -- | -- | -- | -7,752.42 | -- | -- | 0.00 | -- | -- | -- | 4.58 | -- | -38.98 | -- |
| Liminatus Pharma Inc | 0.00 | -2.27m | 10.18m | -- | -- | -- | -- | -- | -0.0872 | -0.0872 | 0.00 | -0.0608 | 0.00 | -- | -- | -- | -77.46 | -- | -- | -- | -- | -- | -- | -- | -- | -12.30 | -- | -- | -- | -- | 28.85 | -- | -- | -- |
| Ainos Inc | 113.04k | -14.96m | 10.61m | 44.00 | -- | 0.7254 | -- | 93.89 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
| Soligenix Inc | 0.00 | -11.46m | 10.99m | 14.00 | -- | 1.41 | -- | -- | -3.66 | -3.66 | 0.00 | 0.7705 | 0.00 | -- | -- | 0.00 | -105.25 | -73.79 | -165.82 | -151.46 | -- | 22.19 | -- | -1,147.93 | -- | -- | 0.00 | -- | -85.78 | -51.89 | -34.62 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -56.98m | 11.14m | 36.00 | -- | 10.29 | -- | -- | -1.22 | -1.22 | 0.00 | 0.0194 | 0.00 | -- | -- | 0.00 | -48.20 | -42.95 | -55.60 | -46.33 | -- | -- | -- | -- | -- | -- | 0.943 | -- | -- | -- | -81.07 | -- | 36.12 | -- |
| KALA BIO Inc | 0.00 | -35.84m | 11.32m | 38.00 | -- | -- | -- | -- | -5.94 | -5.94 | 0.00 | -1.17 | 0.00 | -- | -- | 0.00 | -90.62 | -61.19 | -316.35 | -75.37 | -- | -- | -- | -1,732.87 | -- | -12.71 | 1.44 | -- | -- | -- | 8.74 | -- | -31.05 | -- |
| Longeveron Inc | 1.44m | -21.34m | 11.43m | 25.00 | -- | 1.13 | -- | 7.95 | -1.34 | -1.34 | 0.0909 | 0.4732 | 0.0632 | -- | 6.65 | 57,480.00 | -93.88 | -70.26 | -114.04 | -83.92 | 74.88 | 44.57 | -1,485.11 | -683.81 | -- | -- | 0.00 | -- | 237.38 | -15.76 | -10.86 | -- | 51.32 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -24.14m | 11.47m | 14.00 | -- | 0.4983 | -- | -- | -19.16 | -19.16 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -59.72 | -43.45 | -68.03 | -48.13 | -- | -- | -- | -- | -- | -- | 0.0083 | -- | -- | -- | 11.57 | -- | 22.47 | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.43m | 11.56m | 3.00 | -- | 3,351.42 | -- | -- | -0.0199 | -0.0199 | 0.00 | 0.00002 | 0.00 | -- | -- | 0.00 | -71.49 | 17.96 | -72.49 | 20.49 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -10.35 | -- | -- | -- |
| Moleculin Biotech Inc | 0.00 | -41.36m | 11.69m | 17.00 | -- | -- | -- | -- | -55.88 | -55.88 | 0.00 | -13.60 | 0.00 | -- | -- | 0.00 | -189.07 | -49.52 | -254.72 | -54.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 26.89 | -- | -24.21 | -- |
| BioCardia Inc | 0.00 | -8.54m | 12.10m | 17.00 | -- | 4.60 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 12.33m | 82.00 | -- | 0.3542 | -- | 1.32 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| GT Biopharma Inc | 0.00 | -9.33m | 12.36m | 1.00 | -- | 0.9355 | -- | -- | -3.38 | -3.38 | 0.00 | 0.4957 | 0.00 | -- | -- | 0.00 | -164.22 | -180.24 | -356.99 | -8,448.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -73.25 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -5.06m | 12.45m | 1.00 | -- | 1.62 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Quince Therapeutics Inc's reporting currency: US Dollar USD
18.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 31 Dec 2025 | 2.67m | 4.80% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.79m | 3.22% |
| Millennium Management LLCas of 30 Sep 2025 | 1.39m | 2.49% |
| IEQ Capital LLCas of 31 Dec 2025 | 979.28k | 1.76% |
| Adar1 Capital Management LLCas of 30 Sep 2025 | 775.03k | 1.39% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 538.10k | 0.97% |
| Geode Capital Management LLCas of 31 Dec 2025 | 523.90k | 0.94% |
| Jane Street Capital LLCas of 31 Dec 2025 | 521.07k | 0.94% |
| Marshall Wace LLPas of 31 Dec 2025 | 511.86k | 0.92% |
| Almitas Capital LLCas of 30 Sep 2025 | 494.78k | 0.89% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
